Under construction – not a live service
Sign in
Taking people in RussiaNo phase

Studying which factors predict outcomes in heart failure with preserved ejection fraction

Follows adults with heart failure with preserved ejection fraction over at least 3 years.

Key facts

Who runs it
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Where
Moscow, RussiaSee the site
Trial code
Registry title
Predictors of Poor Prognosis in HFpEF
Status
Recruiting
People taking part
500 people, planned
Started
31 Jan 2022
Expected to end
31 Dec 2026
Type of study
Observational, 2 groups
Record updated
17 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with heart failure and a preserved ejection fraction (HFpEF), who had detailed heart tests and will be followed for at least 3 years.

Age
40 years or older
Sex
All sexes can join
Disease stage
NYHA class II-III heart failure; left ventricular ejection fraction above 50%; high filling pressure in the left side of the heart on echocardiography, at rest or at peak exercise

Main reasons for not taking part

  • Signs of reduced blood flow to the heart muscle during stress echocardiography, or significant narrowing of the main coronary arteries
  • Inherited forms of HFpEF (for example HCM, amyloidosis, Fabry disease)
  • Significant lung disease needing home oxygen or long-term oral steroids, or primary pulmonary artery hypertension
  • Anemia (Hb < 100 g/L) or reduced kidney function (eGFR < 30 mL/min/1.73 m2)
  • Heart failure exacerbation less than 3 months before joining

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Signed and data informed consent
  • New York Heart Association (NYHA) class II-III heart failure
  • Left ventricular ejection fraction > 50%
  • Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise

Who cannot take part

  • Exacerbation of heart failure less than 3 months prior to study entry
  • Evidence of myocardial ischemia during stress echocardiography
  • Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.)
  • Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion
  • Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy)
  • Primary pulmonary artery hypertension
  • Significant left-sided structural valve disease
  • Non-cardiac conditions that complicate/exclude participation in the study
  • Anemia (Hb < 100 g/L)
  • Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (CKD-EPI)
  • Significant lesions of the main coronary arteries

Where in Russia

  • Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian FederationMoscow, RussiaContact: Artem Ovchinnikov, MD, PhD, DScTaking people

About the trial

What the trial wants to find out

Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.

The 2 groups in the trial

  • with primary outcome

    Patients with HFpEF who experienced primary outcome (were hospitalized for HF or died)

  • without primary outcome

    Patients with HFpEF who survived without hospitalization for HF

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction
Plain-language title
Studying which factors predict outcomes in heart failure with preserved ejection fractionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 April 2026